- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03524352
the Prophylaxis of Recurrent Pouchitis After Fecal Microbiota Transplant in UC With Ileo-anal Anastomosis (POCA)
Prospective Multicenter Randomized Controlled Double-blind Label Study of the Prophylaxis of Recurrent Pouchitis After Fecal Microbiota Transplant in UC With Ileo-anal Anastomosis
Ulcerative colitis (UC) is a chronic inflammatory digestive (IBD) disease medically treated with corticosteroids, aminosalicylates, immunomodulators, and biologics. Almost one third of UC patients will require surgical interventions because of fulminant colitis, dysplasia, cancer, or medical refractory diseases. Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the current standard surgical intervention. Anastomotic leak, pouch failure, pelvic sepsis, and pouch ischemia can occur after the procedure, but the most common long-term complication is pouchitis, an idiopathic inflammatory condition involving the ileal reservoir. Symptoms of pouchitis are increased stool frequency, urgency, incontinence, bloody stools, abdominal or pelvic discomfort, fatigue, malaise, and fever. The prevalence of pouchitis ranges from 23 to 46 %, with an annual incidence up to 40 %. Though the majority of initial cases of pouchitis are easily managed with a short course of antibiotics, in about 5 to 15 % of cases, inflammation of the pouch becomes chronic with very few treatments available.
Fecal microbiota transplantation (FMT) is a novel therapy to transfer normal intestinal flora from a healthy donor to a patient with a medical condition potentially caused by disrupted homeostasis of intestinal microbiota or dysbiosis. FMT has been widely used in refractory Clostridium difficile infection (CDI) and recently it has gained popularity for treatment of inflammatory bowel disease (IBD). Previous studies suggested that manipulating the composition of intestinal flora through antibiotics, probiotics, and prebiotic achieved significant results for treating acute episodes of UC-associated pouchitis. However, currently there is no established effective treatment for chronic antibiotic dependent pouchitis. Our project aims to evaluate the delay of relapse in chronic recurrent pouchitis after FMT versus sham transplantation.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Trang POISSON
- Phone Number: +33 2 40 08 75 59
- Email: caroline.trang@chu-nantes.fr
Study Locations
-
-
-
Angers, France
- Not yet recruiting
- CHU Angers
-
Contact:
- DIB
-
Clermont-Ferrand, France
- Recruiting
- CHU Estaing
-
Contact:
- BUISSON
-
Clichy, France
- Recruiting
- Hôpital Beaujon, Clichy
-
Contact:
- BOUHNIK
-
Créteil, France
- Recruiting
- CHU Henry Mondor
-
Contact:
- UZZAN
-
Lille, France
- Recruiting
- CHU Claude Huriez
-
Contact:
- NACHURY
-
Lyon, France
- Recruiting
- CHU Lyon Sud
-
Contact:
- NANCEY
-
Nantes, France
- Recruiting
- CHU of Nantes
-
Contact:
- Trang
- Email: caroline.trang@chu-nantes.fr
-
Nice, France
- Recruiting
- CHU de l'Archet 2
-
Contact:
- HEBUTERNE
-
Paris, France
- Recruiting
- Hôpital Saint Antoine
-
Contact:
- Sokol
-
Pessac, France
- Recruiting
- Groupe Hospitalier Sud- Hopital Haut-lévêque
-
Contact:
- LAHARIE
-
Rennes, France
- Recruiting
- CHU Pontchaillou
-
Contact:
- BOUGUEN
-
Toulouse, France
- Recruiting
- CHU Toulouse
-
Contact:
- ALRIC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
4.2. INCLUSION CRITERIA
Subjects must satisfy the following criteria to be enrolled in the study:
- Male or female ≥ 18 years at the time of signing the informed consent form (ICF).
- Subject must understand and voluntarily sign an ICF prior to conduct the study related assessments/procedure.
- Willing and able to adhere to the study visit scheduled and other protocol requirements.
- Subjects must have been operated with ileal pouch anal anastomosis (IPAA) with a duration of at least 6 month prior the screening visit.
- Subject must have a diagnosis of recurrent pouchitis defined as at least 2 episodes in the last year or relapsing immediately after a reasonable response to antibiotherapy (the antifungal medication is allowed until the day before transplantation).
- Subject must be in remission with a Pouchitis Disease Activity Index (PDAI) < 7 at the screening
- Subject must affiliation with social security system or beneficiary from such system
- Female of childbearing potential must have a negative pregnancy test at screening and must agree to practice effective methods of contraception
4.3. NON-INCLUSION CRITERIA
Subjects who meet any of the following non inclusion criteria could not be enrolled in this study:
- Crohn disease or indeterminate colitis
- Anastomotic stenosis
- Subject with prior treatment by probiotic within 3 month prior to the transplantation visit
- Subject with prior treatment by corticosteroids within 6 weeks prior to the transplantation visit
- Subject with prior treatment by immunosuppressors within 3 month prior to the transplantation visit
- Prior treatment with a biologic within 3 month prior the transplantation visit
- Documented active infection of any kind in the last 6 months likely to require anti-infective treatment during the next months
- Absolute neutrophil count (ANC) < 1.5 x 109 /L (1,500 mm3)
- Infection with chronic HIV
- Pregnant female or breastfeeding
- Chronic medical or psychiatric disease that may interfere with subject's ability to comply with study procedures
- Administration of investigational drug within 3 months prior to planned FMT
- Adults under guardianship, Safeguard justice or trusteeship
- Subject with difficulty in follow-up (vacation, job transfer, geographical distance, lack of motivation).
- Patients with contraindication to colonoscopy or anesthesia (if necessary)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo
|
sterile saline
|
Experimental: fecal microbiota
|
fecal microbiota in suspension
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of days between the date of transplantation and the date of relapse according to physiological and endoscopic parameter (pochitis disease activity index)
Time Frame: 106 weeks
|
106 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of relapse rate according to physiological and endoscopic parameter (pochitis disease activity index)
Time Frame: 24 weeks
|
24 weeks
|
Number of relapse rate according to pochitis disease activity index (physiological and endoscopic parameter)
Time Frame: 52 weeks
|
52 weeks
|
Number of days within the transplantation and the instauration of an antibiotherapy or alternative treatment
Time Frame: 52 weeks
|
52 weeks
|
Number of adverse events
Time Frame: 104 weeks
|
104 weeks
|
Number of fecal microbiota engraftment by 16S sequencing
Time Frame: 8 weeks
|
8 weeks
|
Number of evolution of health-related to disability according to physiological and endoscopic parameter (pochitis disease activity index)
Time Frame: weeks -5
|
weeks -5
|
Number of evolution of health-related to disability according to physiological and endoscopic parameter (pochitis disease activity index)
Time Frame: 0 week
|
0 week
|
Number of evolution of health-related to disability according to physiological and endoscopic parameter (pochitis disease activity index)
Time Frame: 8 weeks
|
8 weeks
|
Number of evolution of health-related to disability according to physiological and endoscopic parameter (pochitis disease activity index)
Time Frame: 24 weeks
|
24 weeks
|
Number of evolution of health-related to disability according to physiological and endoscopic parameter (pochitis disease activity index)
Time Frame: 52 weeks
|
52 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC17_0021
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pouchitis
-
Cedars-Sinai Medical CenterTerminatedPouchitis | Ileal Pouch | Ileal PouchitisUnited States
-
Maia KayalNot yet recruitingPouchitis | Chronic PouchitisUnited States
-
National Institute of Diabetes and Digestive and...Completed
-
Universitaire Ziekenhuizen KU LeuvenJanssen, LPRecruiting
-
University of North Carolina, Chapel HillThe Broad Foundation; Crohn's and Colitis Foundation; OpenBiomeTerminated
-
Virginia O. ShafferCompletedUlcerative Colitis Associated PouchitisUnited States
-
Ocera TherapeuticsCompleted
Clinical Trials on fecal microbiota
-
The University of Texas Health Science Center,...TerminatedRecurrent C. Difficile InfectionUnited States
-
The Second Hospital of Nanjing Medical UniversityRecruiting
-
Madhusudan (Madhu) Grover, MBBSRecruiting
-
Medical University of GrazBristol-Myers SquibbTerminatedMalignant Melanoma Stage III | Malignant Melanoma Stage IV | Fecal Microbiota TransplantationAustria
-
Chinese University of Hong KongActive, not recruitingIrritable Bowel Syndrome | Fecal Microbiota TransplantationHong Kong
-
University Hospital, GhentResearch Foundation FlandersRecruitingResistance BacterialBelgium
-
The First Affiliated Hospital of Nanchang UniversityCompletedAcute Pancreatitis | Intestinal Bacteria Flora Disturbance | Fecal Microbiota Transplantation | Intestinal DysfunctionChina
-
Jinling Hospital, ChinaUnknown
-
The First Affiliated Hospital of Soochow UniversityRecruiting
-
Duke UniversityRecruitingClostridium Difficile ColitisUnited States